Literature DB >> 4674080

Effect of urea on the hemagglutinating and complement-fixing antigens of type 2 Dengue virus.

R A Cornesky, W M Hammon, R W Atchison, G E Sather.   

Abstract

Sephadex G-200 filtration was used for fractionating dengue type 2 (DEN-2)-infected suckling mouse brain (SMB) supernatant fluids. The high-molecular-weight fraction, which was eluted in the void volume, showed no increase in type specificity when tested against immune ascitic fluid to the four prototype dengue viruses. A void-volume fraction obtained after the infected SMB supernatant fluids were treated with urea displayed significant increases in complement fixation (CF) type specificity. Immune ascitic fluid prepared against the more typespecific DEN-2 antigen demonstrated neutralizing ability and greater CF type specificity. When DEN-2 sucrose-acetone-extracted hemagglutinating (HA) antigens were treated with 6 m urea at 37 C for various time intervals, all HA antigen was destroyed in 15 min. Urea treatment of infected SMB supernatant fluids indicated that the CF antigens were more stable to the effect of urea than were the HA antigens. After urea treatment of the SMB supernatant fluids, the CF type specificity increased as the hemagglutination inhibition titer decreased.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4674080      PMCID: PMC419317          DOI: 10.1128/iai.6.6.952-957.1972

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  Production and characterization of arbovirus antibody in mouse ascitic fluid.

Authors:  W E Brandt; E L Buescher; F M Hetrick
Journal:  Am J Trop Med Hyg       Date:  1967-05       Impact factor: 2.345

2.  Studies on mouse leukemia viruses. I. Isolation and characterization of a group-specific antigen.

Authors:  W Schäfer; F A Anderer; H Bauer; L Pister
Journal:  Virology       Date:  1969-07       Impact factor: 3.616

3.  Physical and biological properties of dengue-2 virus and associated antigens.

Authors:  T J Smith; W E Brandt; J L Swanson; J M McCown; E L Buescher
Journal:  J Virol       Date:  1970-04       Impact factor: 5.103

4.  Application of immunodiffusion methods to the antigenic analysis of dengue viruses. I. Precipitation-in-gel double diffusion in two imensions.

Authors:  A N Ibrahim; W M Hammon
Journal:  J Immunol       Date:  1968-01       Impact factor: 5.422

5.  Antigenic variants of arboviruses. IV. The distinctive antigenic properties of virus clones propagated in different hosts.

Authors:  J R Henderson
Journal:  J Immunol       Date:  1968-09       Impact factor: 5.422

6.  Partial purification and characterization of a dengue virus soluble complement-fixing antigen.

Authors:  W E Brandt; D Chiewslip; D L Harris; P K Russell
Journal:  J Immunol       Date:  1970-12       Impact factor: 5.422

7.  Immunoprecipitation analysis of soluble complement-fixing antigens of dengue viruses.

Authors:  P K Russell; D Chiewsilp; W E Brandt
Journal:  J Immunol       Date:  1970-10       Impact factor: 5.422

8.  Characterization of virus- and endotoxin-induced interferons obtained from the serum and urine of rabbits.

Authors:  Y H Ke; M Ho
Journal:  J Virol       Date:  1967-10       Impact factor: 5.103

9.  Proteins of vesicular stomatitis virus. II. Immunological comparisons of viral antigens.

Authors:  C Y Kang; L Prevec
Journal:  J Virol       Date:  1970-07       Impact factor: 5.103

10.  Observations related to pathogenesis of dengue hemorrhagic fever. I. Experience with classification of dengue viruses.

Authors:  S B Halstead; S Udomsakdi; P Simasthien; P Singharaj; P Sukhavachana; A Nisalak
Journal:  Yale J Biol Med       Date:  1970-04
View more
  1 in total

1.  Early clinical and laboratory risk factors of intensive care unit requirement during 2004-2008 dengue epidemics in Singapore: a matched case-control study.

Authors:  Junxiong Pang; Tun-Linn Thein; Yee-Sin Leo; David C Lye
Journal:  BMC Infect Dis       Date:  2014-12-05       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.